PNPLA3 and metabolic dysfunction-associated steatotic liver disease: Kuttner et al. looked at the impact of short-term omega-3 fatty acid supplementation (1840 mg eicosapentaenoic and 1520 mg docosahexaenoic acid) on hepatic steatosis in carriers of the PNPLA3 rs738409 variant, but did not find significant changes in hepatic steatosis in patients with NAFLD who were homozygous for the PNPLA3 I148M risk allele [40].